These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 19604045)

  • 1. Slow accumulation of HIV resistance mutations: implications for resource-limited settings?
    Stevens WS
    J Infect Dis; 2009 Sep; 200(5):670-2. PubMed ID: 19604045
    [No Abstract]   [Full Text] [Related]  

  • 2. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
    J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessments of HIV drug resistance mutations in resource-limited settings.
    Jordan MR
    Clin Infect Dis; 2011 Apr; 52(8):1058-60. PubMed ID: 21460325
    [No Abstract]   [Full Text] [Related]  

  • 4. The K65R mutation: selection, frequency, and possible consequences.
    Moyle GJ
    AIDS Read; 2004 Nov; 14(11):595-7, 601-3. PubMed ID: 15570671
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV/AIDS. Tangled patent dispute over 'free' drug-resistance database.
    Cohen J
    Science; 2009 Feb; 323(5918):1156-7. PubMed ID: 19251598
    [No Abstract]   [Full Text] [Related]  

  • 6. The benefits of HIV resistance testing in optimizing drug discovery.
    Heilek-Snyder G; Bean P
    Am Clin Lab; 2002 Oct; 21(8):13-4. PubMed ID: 12440169
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV drug resistance and you. Resistance overview. A look at the basics.
    Munk B
    Posit Aware; 2006; Spec No():6-9. PubMed ID: 16583502
    [No Abstract]   [Full Text] [Related]  

  • 8. New insights into HIV resistance testing: nursing guidelines and implications.
    Kirton CA; Kurtyka D; Sterken DJ
    J Assoc Nurses AIDS Care; 2007; 18(3):74-86. PubMed ID: 17570302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why HIV drug resistance matters: an overview.
    Learned J
    Posit Aware; 2005; 16(5):26-30. PubMed ID: 16220604
    [No Abstract]   [Full Text] [Related]  

  • 10. [Resistance investigations during HIV-therapy is necessary].
    Schattenfroh S
    Dtsch Med Wochenschr; 1998 Feb; 123(7):A7. PubMed ID: 9505940
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV suppression and risk of drug resistance mutations.
    Phillips AN; Loveday C; Johnson MA
    AIDS; 1998 Oct; 12(14):1930. PubMed ID: 9792396
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV drug resistance testing: an update for the clinician.
    Rice HL; Zolopa AR
    AIDS Clin Care; 2001 Oct; 13(10):89-91, 94-6, 100. PubMed ID: 11590921
    [No Abstract]   [Full Text] [Related]  

  • 13. Accrued HIV evidence turns treatment dogma on its head.
    Check E
    Nature; 2003 Aug; 424(6951):866. PubMed ID: 12931150
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiretroviral rounds. Resistance: how do you know if you don't know?
    Campbell TB; Katzenstein D
    AIDS Clin Care; 2005 Mar; 17(3):26-7. PubMed ID: 15828117
    [No Abstract]   [Full Text] [Related]  

  • 15. Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USA.
    Hicks CB
    AIDS Clin Care; 2008 Aug; 20(8):64. PubMed ID: 18814369
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV resistance and the developing world.
    Gupta RK; Pillay D
    Int J Antimicrob Agents; 2007 May; 29(5):510-7. PubMed ID: 17346940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical data marshalled to treat HIV.
    Clarke T
    Nature; 2003 Jun; 423(6942):791. PubMed ID: 12815390
    [No Abstract]   [Full Text] [Related]  

  • 18. A single case of multidrug-resistant HIV and rapid disease progression.
    O'Rourke M
    AIDS Clin Care; 2005 Mar; 17(3):21-2. PubMed ID: 15828115
    [No Abstract]   [Full Text] [Related]  

  • 19. When do minority drug-resistant HIV-1 variants have a major clinical impact?
    Heneine W
    J Infect Dis; 2010 Mar; 201(5):647-9. PubMed ID: 20102273
    [No Abstract]   [Full Text] [Related]  

  • 20. Outsmarting HIV.
    Fallon SJ
    Posit Aware; 2003; 14(2):37. PubMed ID: 12693374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.